Direvo Biotech AG Announces Validation of bestMab(TM)

COLOGNE, GERMANY--(Marketwire - May 06, 2008) - DIREVO Biotech AG announced today that it has validated its "bestMab™" platform through the generation of an optimized version of the anti-inflammatory antibody, Adalimumab (Humira®), with unprecedentedly strong binding properties. optiMIRA™ shows 300-times tighter antigen binding than Humira®, and more than 15- fold tighter binding than the previously most advanced optimized Humira® derivative, which was generated using display technology. The results of this study were presented on May 1st, 2008 at the Fourth Annual Protein Engineering Summit (PEGS) conference in Boston, USA. The presentation can be viewed at www.direvo.com/bestMab/PEGS